Jason Hollar New CFO of Cardinal Health

As Tenneco’s executive vice president and chief financial officer, Jason Hollar was responsible for financial planning and analysis, accounting and reporting, tax, treasury and investor relations for the company.

Mr. Hollar joined Tenneco in June 2017 from Sears Holding Corporation, where he served as chief financial officer. Prior to Sears, Mr. Hollar worked with both Delphi Automotive and Navistar in a number of senior finance roles. He served as Delphi’s corporate controller and as vice president of finance for the company’s powertrain systems division, which also included oversight of the Europe, Middle East and Africa region. At Navistar, he held finance positions of increasing responsibility in the company’s engine group, South America operations and corporate financial planning and analysis.

Mr. Hollar received his Master of Business Administration from The University of Chicago and his bachelor’s degree in business from Indiana University.

“We are pleased to welcome Jason to the Cardinal Health family,” said Cardinal Health CEO Mike Kaufmann. “With his deep executive experience, as well as his expertise leading in dynamic environments, Jason Hollar will be a strong partner to me and the rest of our team. I’d like to thank Dave Evans for his exceptional contributions and leadership as our interim CFO. Dave will partner with Jason Hollar in the coming weeks to ensure a smooth transition and as we continue to create value in a changing marketplace.”

Mr. Hollar’s experience spans industries and geographies. In addition to serving as CFO of Tenneco and previously as CFO of Sears Holding Corporation, Mr. Hollar held senior finance roles at companies including Delphi and Navistar, demonstrating both breadth and depth across financial disciplines. He also managed regional operations around the globe and led multiple transformative initiatives to drive corporate strategies.

As Cardinal Health CFO, Jason Hollar will lead financial activities across the enterprise, including financial strategy, capital deployment, treasury, tax, investor relations, accounting and reporting. He will report to Mr. Kaufmann as a member of the company’s Executive Committee and will succeed Dave Evans, who will continue to serve as CFO of Cardinal Health through May 11.

I am excited to join the Cardinal Health team,” said Mr. Hollar. “I look forward to partnering with Mike, his leadership team and the Finance organization to advance the company’s strategic transformation at this pivotal time in healthcare.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”